Medicine and Dentistry
Pirfenidone
100%
Esomeprazole
72%
Idiopathic Pulmonary Fibrosis
45%
Pulmonary Fibrosis
36%
Collagen
27%
Drug
27%
Chemotherapeutic Agent
27%
Cells
27%
In Vitro
18%
Silo-Filler's Disease
18%
Cell Migration
18%
Fibrosis
18%
Lung Fibroblast
18%
Therapeutic Procedure
18%
Diseases
9%
Biological Product
9%
Etiology
9%
Cell Proliferation
9%
Biological Phenomena and Functions Concerning the Entire Organism
9%
Cell Culture
9%
Combination Therapy
9%
Monotherapy
9%
Gastroesophageal Reflux
9%
Proton-Pump Inhibitor
9%
Extracellular Matrix
9%
Keratin
9%
Antiproliferative Activity
9%
Alpha Smooth Muscle Actin
9%
Collagen Gel
9%
Nintedanib
9%
Differentiation
9%
Family
9%
Inpatient
9%
Animal Study
9%
Myofibroblast
9%
Pharmacology, Toxicology and Pharmaceutical Science
Pirfenidone
100%
Esomeprazole
72%
Clinical Study
54%
Fibrosing Alveolitis
45%
Lung Fibrosis
36%
Collagen
27%
Drug
27%
Lung Disease
18%
Mouse Model
18%
Fibrosis
18%
Diseases
9%
Biological Product
9%
Monotherapy
9%
Proton Pump Inhibitor
9%
Combination Therapy
9%
Preclinical Study
9%
Etiology
9%
Keratin
9%
Collagen Gel
9%
Alpha Smooth Muscle Actin
9%
Gastroesophageal Reflux
9%
Biochemistry, Genetics and Molecular Biology
Esomeprazole
72%
Collagen
27%
Fibroblast
18%
Cell Migration
18%
Mouse Model
18%
In Vivo Study
18%
Myofibroblast
9%
Cell Proliferation
9%
Actin
9%
Preclinical Study
9%
Cell Culture
9%
Animal Experiment
9%
Biological Phenomena and Functions Concerning the Entire Organism
9%
Bioinformatics
9%
Keratin
9%
Antiproliferative Activity
9%
Proton Pump
9%
Collagen Gel
9%